Relmada Therapeutics (RLMD) Debt to Equity (2014 - 2018)
Relmada Therapeutics (RLMD) reported Debt to Equity of -$0.89 for Q3 2018, down 140.67% year-over-year from $2.18 in Q3 2017, and up 28.57% quarter-over-quarter from -$1.24 in Q2 2018.
Relmada Therapeutics (RLMD) Debt to Equity (2014 - 2018) Analysis & Trends
Relmada Therapeutics (RLMD) has 5 years of Debt to Equity data on file, last reported at -$0.89 in Q3 2018.
- Debt to Equity for Q3 2018 came in at -$0.89, down 140.67% year-over-year; the trailing twelve-month figure through Sep 2018 was -$0.89 (down 140.67% YoY), and the FY2018 annual result was -$1.24, down 1131.94% from the prior year.
- Debt to Equity rose to -$0.89 in Q3 2018 per RLMD's latest filing, from -$1.24 in the prior quarter.
- Over five years, Debt to Equity peaked at $9.81 in Q1 2015 and troughed at -$23.07 in Q2 2014.
- A 5-year average of -$0.14 and a median of $0.12 in 2017 frame the typical range for Debt to Equity.
- The sharpest annual moves came in 2017 and 2018: Debt to Equity jumped 6043.44% in 2017, then plunged 2495.95% in 2018.
- A 5-year view of Debt to Equity shows it stood at $5.79 in 2014, then plunged by 97.88% to $0.12 in 2015, then slipped by 8.9% to $0.11 in 2016, then jumped by 6043.44% to $6.88 in 2017, then plunged by 112.9% to -$0.89 in 2018.
- Business Quant data shows RLMD's Debt to Equity at -$0.89 in Q3 2018, -$1.24 in Q2 2018, and -$2.39 in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.32 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Relmada Therapeutics | 581.07 Mn | 581.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | -0.89 |
| Jun 30, 2018 | -1.24 |
| Mar 31, 2018 | -2.39 |
| Dec 31, 2017 | 6.88 |
| Sep 30, 2017 | 2.18 |
| Jun 30, 2017 | 0.12 |
| Mar 31, 2017 | 0.10 |
| Dec 31, 2016 | 0.11 |
| Sep 30, 2016 | 0.17 |
| Jun 30, 2016 | 0.13 |
| Mar 31, 2016 | 0.06 |
| Dec 31, 2015 | 0.12 |
| Sep 30, 2015 | 0.34 |
| Jun 30, 2015 | 1.59 |
| Mar 31, 2015 | 9.81 |
| Dec 31, 2014 | 5.79 |
| Sep 30, 2014 | -2.26 |
| Jun 30, 2014 | -23.07 |